ZA923557B - Composition of angiotensin-II receptor antagonists and calcium channel blockers - Google Patents
Composition of angiotensin-II receptor antagonists and calcium channel blockersInfo
- Publication number
- ZA923557B ZA923557B ZA923557A ZA923557A ZA923557B ZA 923557 B ZA923557 B ZA 923557B ZA 923557 A ZA923557 A ZA 923557A ZA 923557 A ZA923557 A ZA 923557A ZA 923557 B ZA923557 B ZA 923557B
- Authority
- ZA
- South Africa
- Prior art keywords
- angiotensin
- composition
- receptor antagonists
- calcium channel
- channel blockers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70074091A | 1991-05-15 | 1991-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA923557B true ZA923557B (en) | 1993-11-15 |
Family
ID=24814683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA923557A ZA923557B (en) | 1991-05-15 | 1992-05-15 | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0584250A1 (ja) |
JP (1) | JP2930252B2 (ja) |
AU (1) | AU664375B2 (ja) |
CA (1) | CA2103276A1 (ja) |
CZ (1) | CZ281570B6 (ja) |
IE (1) | IE921534A1 (ja) |
IL (1) | IL101858A (ja) |
MX (1) | MX9202243A (ja) |
NZ (1) | NZ242724A (ja) |
WO (1) | WO1992020342A1 (ja) |
ZA (1) | ZA923557B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3057471B2 (ja) | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンii介在性諸疾患の予防または治療剤 |
JP3883205B2 (ja) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | アンギオテンシン▲ii▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療 |
WO1996028185A2 (en) | 1995-03-16 | 1996-09-19 | Pfizer Inc. | Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor |
TR200100062T2 (tr) | 1998-07-10 | 2001-06-21 | Novartis Ag | Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu |
US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
US7481803B2 (en) * | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
JP4000505B2 (ja) | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
GB0008332D0 (en) * | 2000-04-04 | 2000-05-24 | Pfizer Ltd | Treament |
AU2001267404A1 (en) * | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
WO2002043807A2 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
AU2004208615C1 (en) | 2003-01-31 | 2010-05-13 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
CA2020073A1 (en) * | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
EP0565634B1 (en) * | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
-
1992
- 1992-05-13 NZ NZ242724A patent/NZ242724A/xx not_active IP Right Cessation
- 1992-05-14 JP JP5500110A patent/JP2930252B2/ja not_active Expired - Lifetime
- 1992-05-14 IL IL10185892A patent/IL101858A/en not_active IP Right Cessation
- 1992-05-14 CA CA002103276A patent/CA2103276A1/en not_active Abandoned
- 1992-05-14 CZ CS932351A patent/CZ281570B6/cs not_active IP Right Cessation
- 1992-05-14 MX MX9202243A patent/MX9202243A/es unknown
- 1992-05-14 EP EP92912707A patent/EP0584250A1/en not_active Withdrawn
- 1992-05-14 WO PCT/US1992/003873 patent/WO1992020342A1/en not_active Application Discontinuation
- 1992-05-14 AU AU20269/92A patent/AU664375B2/en not_active Expired
- 1992-05-15 ZA ZA923557A patent/ZA923557B/xx unknown
- 1992-07-01 IE IE153492A patent/IE921534A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPH06508128A (ja) | 1994-09-14 |
EP0584250A4 (ja) | 1994-03-30 |
CZ281570B6 (cs) | 1996-11-13 |
AU664375B2 (en) | 1995-11-16 |
EP0584250A1 (en) | 1994-03-02 |
NZ242724A (en) | 1994-09-27 |
IL101858A (en) | 1996-08-04 |
IL101858A0 (en) | 1992-12-30 |
CA2103276A1 (en) | 1992-11-16 |
WO1992020342A1 (en) | 1992-11-26 |
IE921534A1 (en) | 1992-11-18 |
MX9202243A (es) | 1992-11-01 |
JP2930252B2 (ja) | 1999-08-03 |
AU2026992A (en) | 1992-12-30 |
CZ235193A3 (en) | 1994-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA923557B (en) | Composition of angiotensin-II receptor antagonists and calcium channel blockers | |
GB2276560B (en) | Bone cement mixing device | |
EP0538989A3 (en) | Well cement compositions and their use | |
ZA92990B (en) | Calcium channel antagonists and methodology for their identification | |
SI0838217T1 (en) | Cosmetic composition containing neuropeptide Y receptor antagonist | |
IL99246A0 (en) | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them | |
AR243487A1 (es) | Cemento mezclado de resistencia realzada, composicion formada a partir del mismo, y procedimiento para realzar su resistencia. | |
ZA93550B (en) | Azabricyclic compounds as calcium channel antagonists | |
KR19987002866A (en) | Cement composition | |
EP0828751A4 (en) | HUMAN NEUROPEPTIDE RECEPTOR | |
PL311272A1 (en) | Antagonists of endotheline receptors | |
IL99539A0 (en) | Fibrinogen receptor antagonists and pharmaceutical compositions containing them | |
ZA907720B (en) | Enhanced blended and portland cement compositions | |
ZA961325B (en) | Cement composition | |
BR9407743A (pt) | Composiçao oral de peróxido de cálcio-bicarbonato | |
AU9069191A (en) | Use of angiotensin ii receptor antagonists in the prevention of restinosis | |
AU5449194A (en) | Combinations of angiotensin-ii receptor antagonists and diuretics | |
GB9105246D0 (en) | Cement restrictor | |
GB9320799D0 (en) | Fibrinogen receptor antagonists | |
ZA922265B (en) | Somatostatin receptor | |
IL101368A0 (en) | Somatostatin receptor | |
KR19987002821A (en) | Cement composition | |
ZA924350B (en) | Novel cement additives and hydraulic cement mixes containing them | |
IE900471L (en) | Calcium antagonists | |
HU9300302D0 (en) | Cdns-s coding gastrine and cck-b receptors |